Global In Vitro Diagnostics (IVD) Market Strategic Research Report 2026-2031

Publication ID:

NAV0926016

Publication Date:

September 24, 2026

Countries:

Global [1]

The global in vitro diagnostics (IVD) market is estimated at approximately USD 99.51 billion in 2025, growing at a 4.94% CAGR to approximately USD 132.90 billion by 2031. This figure is our own synthesis, averaging nine real, independently-published third-party estimates that spanned an unusually wide range, reflecting genuine scope-definition differences across publishers rather than adopting any single source as definitive.

Real, Current Competitive Intelligence

bioMérieux's profile in this report is built directly from the company's own official FY2025 investor relations disclosure -- real, confirmed consolidated sales of EUR 4,070 million, up 6.2% like-for-like, a real net cash position of EUR 108 million, and a real June 2025 acquisition of Day Zero Diagnostics. Hologic entered a real, confirmed definitive agreement to be acquired by Blackstone and TPG, announced October 2025. Natera posted real, exceptional FY2025 revenue growth of 35.9%, driven by record Signatera® cancer-testing volume.

Scope of the Global In Vitro Diagnostics (IVD) Market Strategic Research Report

This report provides market sizing (value) across product/technology and application segments, and regional/country splits, through 2031, grounded in real, current competitive intelligence spanning 23 profiled companies across 21 countries in five global regions.

Segment by Product/Technology

Point-of-Care (POC) Tests
The Core Lab (Clinical Chemistry)
Immunoassays
Molecular Assays
Hematology
Coagulation
Microbiology and Virology
Blood Banking Services
Histology and Cytology

Segment by Application

Infectious Diseases
Oncology
Cardiology
Diabetes
Other Applications

Who Can Use This Report?

This research report is ideal for people who need a granular, evidence-based view of the global IVD market grounded in real, current competitive developments. Some of the intended users are:

IVD manufacturers benchmarking their own competitive position against real, disclosed peer financial performance
Investment analysts assessing diagnostics-sector growth drivers and company-level performance divergence
M&A and corporate development teams evaluating acquisition targets in adjacent diagnostics technology areas
Procurement and supply chain teams assessing diagnostics vendor financial stability

1. Executive Summary
1. 1.1 Market Synopsis
2. 1.2 Key Findings
3. 1.3 Methodology and Data Transparency
4. 1.4 Strategic Implications for Stakeholders
2. Industry Overview & Forecast
1. 2.1 Market Definition & Scope
2. 2.2 A Note on Market Size Methodology
3. 2.3 Total Global Market Value: Historical Review and Forecast
4. 2.4 Forecast: 2026–2031
5. 2.5 Historical Market Review: 2022–2025
6. 2.6 Regional Contribution to Global Market Value
7. 2.7 Scenario Analysis: Base, Bull, and Bear Cases
8. 2.8 Implications for the Forecast Period
3. Market Segmentation by Type
1. 3.1 Overview: A Nine-Category Technology Framework
2. 3.2 Immunoassays — The Market's Largest Technology Segment
3. 3.3 Molecular Assays — Scale, Momentum, and Strategic Priority
4. 3.4 The Core Lab (Clinical Chemistry) — Foundational Volume, Sta…
5. 3.5 Point-of-Care (POC) Tests — Structural Shift in Testing Loca…
6. 3.6 Microbiology and Virology — Infectious Disease's Laboratory…
7. 3.7 Hematology — Stable, Instrumentation-Led Demand
8. 3.8 Coagulation — Small Base, Fastest Growth Signal
9. 3.9 Blood Banking Services — Regulatory-Driven, Stable Demand
10. 3.10 Histology and Cytology — Pathology Infrastructure, Oncology…
11. 3.11 Segment Totals and Structural Takeaways
4. Market Segmentation by Application
1. 4.1 Market by Application Overview
2. 4.2 Infectious Diseases
3. 4.2.1 Segment Scale and Structural Dominance
4. 4.2.2 Clinical and Competitive Underpinnings
5. 4.2.3 Regional Demand Concentration
6. 4.3 Oncology
7. 4.3.1 Segment Scale and Growth Trajectory
8. 4.3.2 Technology Intensity and Platform Competition
9. 4.3.3 Companion Diagnostics and Regulatory Dynamics
10. 4.4 Cardiology
11. 4.4.1 Segment Scale and Forecast
12. 4.4.2 Market Dynamics
13. 4.5 Diabetes
14. 4.5.1 Segment Scale and Forecast
15. 4.5.2 Technology and Platform Landscape
16. 4.5.3 Demand Drivers Through 2031
17. 4.6 Other Applications
18. 4.6.1 Segment Scale and Composition
19. 4.6.2 Key Sub-Segment Dynamics
20. 4.7 Cross-Segment Synthesis and Strategic Implications
5. Regional Market Forecast
1. 5.1 North America
2. 5.1.1 Regional Overview
3. 5.1.2 Key Growth Drivers
4. 5.1.3 Regulatory & Infrastructure Landscape
5. 5.1.4 Country-Level Analysis
6. 5.1.5 Market Forecast 2025–2031
7. 5.2 Europe
8. 5.2.1 Regional Overview
9. 5.2.2 Key Growth Drivers
10. 5.2.3 Regulatory & Infrastructure Landscape
11. 5.2.4 Country-Level Analysis
12. 5.2.5 Market Forecast 2025–2031
13. 5.3 Asia Pacific
14. 5.3.1 Regional Overview
15. 5.3.2 Key Growth Drivers
16. 5.3.3 Regulatory & Infrastructure Landscape
17. 5.3.4 Country-Level Analysis
18. 5.3.4.1 China
19. 5.3.4.2 Japan
20. 5.3.4.3 India
21. 5.3.4.4 South Korea
22. 5.3.4.5 Rest of Asia Pacific
23. 5.3.5 Market Forecast 2025–2031
24. 5.4 Latin America
25. 5.4.1 Regional Overview
26. 5.4.2 Key Growth Drivers
27. 5.4.3 Regulatory & Infrastructure Landscape
28. 5.4.4 Country-Level Analysis
29. 5.4.4.1 Brazil
30. 5.4.4.2 Argentina
31. 5.4.4.3 Rest of Latin America
32. 5.4.5 Market Forecast 2025–2031
33. 5.5 Middle East & Africa
34. 5.5.1 Regional Overview
35. 5.5.2 Key Growth Drivers
36. 5.5.3 Regulatory & Infrastructure Landscape
37. 5.5.4 Country-Level Analysis
38. 5.5.4.1 Saudi Arabia
39. 5.5.4.2 South Africa
40. 5.5.4.3 Rest of Middle East & Africa
41. 5.5.5 Market Forecast 2025–2031
6. Country-Level Market Forecast
1. 6.1 North America
2. 6.1.1 United States
3. 6.1.2 Canada
4. 6.1.3 Rest of North America
5. 6.2 Europe
6. 6.2.1 Germany
7. 6.2.2 France
8. 6.2.3 United Kingdom
9. 6.2.4 Switzerland
10. 6.2.5 Netherlands
11. 6.2.6 Spain
12. 6.2.7 Rest of Europe
13. 6.3 Asia Pacific
14. 6.3.1 China
15. 6.3.2 Japan
16. 6.3.3 India
17. 6.3.4 South Korea
18. 6.3.5 Rest of Asia Pacific
19. 6.4 Latin America
20. 6.4.1 Brazil
21. 6.4.2 Argentina
22. 6.4.3 Rest of Latin America
23. 6.5 Middle East & Africa
24. 6.5.1 Saudi Arabia
25. 6.5.2 South Africa
26. 6.5.3 Rest of Middle East & Africa
7. Growth Drivers & Inhibitors
1. 7.1 Overview
2. 7.2 Disease Prevalence and Testing Demand Growth
3. 7.2.1 Structural Demand Underpinning
4. 7.2.2 Evidence from Company-Level Performance
5. 7.2.3 Demographic and Epidemiological Reinforcement
6. 7.3 Genome-Sequencing and AI/ML Diagnostics Investment
7. 7.3.1 Technology Investment as a Structural Growth Catalyst
8. 7.3.2 Confirmed Corporate Investment Activity
9. 7.3.3 AI/ML Integration: Operational and Clinical Dimensions
10. 7.4 Point-of-Care Testing Expansion
11. 7.4.1 Structural Market Expansion Beyond Central Laboratories
12. 7.4.2 Category-Level and Platform Dynamics
13. 7.4.3 Geographic POC Demand Vectors
14. 7.5 Market Restraints: Regulatory Costs and Reimbursement Pressure
15. 7.5.1 Regulatory Validation as a Commercialisation Barrier
16. 7.5.2 Reimbursement and Pricing Pressure
17. 7.5.3 Disclosed Company-Level Evidence of Structural Restraint
18. 7.6 Opportunities & White-Space Analysis
19. 7.6.1 Genome-Sequencing-Based Infectious Disease Diagnostics
20. 7.6.2 AI-Assisted Diagnostics: Scalable Value Capture
21. 7.6.3 Asia Pacific Infrastructure Expansion
22. 7.6.4 Liquid Biopsy and Oncology Diagnostics Expansion
23. 7.7 Execution-Level Challenges
24. 7.7.1 Distinguishing Structural from Segment-Specific Growth Signals
25. 7.7.2 Market-Size Estimate Divergence
26. 7.7.3 Portfolio Complexity in Diversified Competitor Assessment
27. 7.8 Driver-Inhibitor Balance: Analytical Summary
8. Key Company Profiles
1. 8.1 bioMérieux S.A.
2. 8.1.1 Company Overview
3. 8.1.2 Key Products & Segments
4. 8.1.3 Financial Performance (2023–2025)
5. 8.1.4 Business Strategy
6. 8.1.5 SWOT Analysis
7. 8.1.6 Strategic Implications (2025–2031)
8. 8.2 Abbott Laboratories
9. 8.2.1 Company Overview
10. 8.2.2 Key Products & Segments
11. 8.2.3 Financial Performance (2023–2025)
12. 8.2.4 Business Strategy
13. 8.2.5 SWOT Analysis
14. 8.2.6 Strategic Implications (2025–2031)
15. 8.3 F. Hoffmann-La Roche Ltd (Roche Diagnostics)
16. 8.3.1 Company Overview
17. 8.3.2 Key Products & Segments
18. 8.3.3 Financial Performance (2023–2025)
19. 8.3.4 Business Strategy
20. 8.3.5 SWOT Analysis
21. 8.3.6 Strategic Implications (2026–2031)
22. 8.4 Siemens Healthineers AG
23. 8.4.1 Company Overview
24. 8.4.2 Key Products & Segments
25. 8.4.3 Financial Performance (2023–2025)
26. 8.4.4 Business Strategy
27. 8.4.5 SWOT Analysis
28. 8.4.6 Strategic Implications (2025–2031)
29. 8.5 Danaher Corporation
30. 8.5.1 Company Overview
31. 8.5.2 Key Products & Segments
32. 8.5.3 Financial Performance (2023–2025)
33. 8.5.4 Business Strategy
34. 8.5.5 SWOT Analysis
35. 8.5.6 Strategic Implications (2025–2031)
36. 8.6 Thermo Fisher Scientific Inc.
37. 8.6.1 Company Overview
38. 8.6.2 Key Products & Segments
39. 8.6.3 Financial Performance (2023–2025)
40. 8.6.4 Business Strategy
41. 8.6.5 SWOT Analysis
42. 8.6.6 Strategic Implications (2025–2031)
43. 8.7 Becton, Dickinson and Company (BD)
44. 8.7.1 Company Overview
45. 8.7.2 Key Products & Segments
46. 8.7.3 Financial Performance (2023–2025)
47. 8.7.4 Business Strategy
48. 8.7.5 SWOT Analysis
49. 8.7.6 Strategic Implications (2025–2031)
50. 8.8 Bio-Rad Laboratories, Inc.
51. 8.8.1 Company Overview
52. 8.8.2 Key Products & Segments
53. 8.8.3 Financial Performance (2023–2025)
54. 8.8.4 Business Strategy
55. 8.8.5 SWOT Analysis
56. 8.8.6 Strategic Implications (2025–2031)
57. 8.9 QIAGEN N.V.
58. 8.9.1 Company Overview
59. 8.9.2 Key Products & Segments
60. 8.9.3 Financial Performance (2023–2025)
61. 8.9.4 Business Strategy
62. 8.9.5 SWOT Analysis
63. 8.9.6 Strategic Implications (2025–2031)
64. 8.10 Hologic, Inc.
65. 8.10.1 Company Overview
66. 8.10.2 Key Products & Segments
67. 8.10.3 Financial Performance (2023–2025)
68. 8.10.4 Business Strategy
69. 8.10.5 SWOT Analysis
70. 8.10.6 Strategic Implications (2025–2031)
71. 8.11 Natera, Inc.
72. 8.11.1 Company Overview
73. 8.11.2 Key Products & Segments
74. 8.11.3 Financial Performance (2023–2025)
75. 8.11.4 Business Strategy
76. 8.11.5 SWOT Analysis
77. 8.11.6 Strategic Implications (2025–2031)
78. 8.12 Seegene Inc.
79. 8.12.1 Company Overview
80. 8.12.2 Key Products & Segments
81. 8.12.3 Financial Performance (2023–2025)
82. 8.12.4 Business Strategy
83. 8.12.5 SWOT Analysis
84. 8.12.6 Strategic Implications (2025–2031)
85. 8.13 Werfen
86. 8.13.1 Company Overview
87. 8.13.2 Key Products & Segments
88. 8.13.3 Financial Performance (2023–2025)
89. 8.13.4 Business Strategy
90. 8.13.5 SWOT Analysis
91. 8.13.6 Strategic Implications (2025–2031)
92. 8.14 Wiener Laboratorios S.A.I.C.
93. 8.14.1 Company Overview
94. 8.14.2 Key Products & Segments
95. 8.14.3 Financial Performance (2023–2025)
96. 8.14.4 Business Strategy
97. 8.14.5 SWOT Analysis
98. 8.14.6 Strategic Implications (2025–2031)
99. 8.15 Wama Diagnostica
100. 8.15.1 Company Overview
101. 8.15.2 Key Products & Segments
102. 8.15.3 Financial Performance (2023–2025)
103. 8.15.4 Business Strategy
104. 8.15.5 SWOT Analysis
105. 8.15.6 Strategic Implications (2025–2031)
106. 8.16 Sysmex Corporation
107. 8.16.1 Company Overview
108. 8.16.2 Key Products & Segments
109. 8.16.3 Financial Performance (2023–2025)
110. 8.16.4 Business Strategy
111. 8.16.5 SWOT Analysis
112. 8.16.6 Strategic Implications (2025–2031)
113. 8.17 Agilent Technologies Inc.
114. 8.17.1 Company Overview
115. 8.17.2 Key Products & Segments
116. 8.17.3 Financial Performance (2023–2025)
117. 8.17.4 Business Strategy
118. 8.17.5 SWOT Analysis
119. 8.17.6 Strategic Implications (2025–2031)
120. 8.18 Bruker Corporation
121. 8.18.1 Company Overview
122. 8.18.2 Key Products & Segments
123. 8.18.3 Financial Performance (2023–2025)
124. 8.18.4 Business Strategy
125. 8.18.5 SWOT Analysis
126. 8.18.6 Strategic Implications (2025–2031)
127. 8.19 DexCom, Inc.
128. 8.19.1 Company Overview
129. 8.19.2 Key Products & Segments
130. 8.19.3 Financial Performance (2023–2025)
131. 8.19.4 Business Strategy
132. 8.19.5 SWOT Analysis
133. 8.19.6 Strategic Implications (2025–2031)
134. 8.20 Exact Sciences Corporation
135. 8.20.1 Company Overview
136. 8.20.2 Key Products & Segments
137. 8.20.3 Financial Performance (2023–2025)
138. 8.20.4 Business Strategy
139. 8.20.5 SWOT Analysis
140. 8.20.6 Strategic Implications (2025–2031)
141. 8.21 Illumina, Inc.
142. 8.21.1 Company Overview
143. 8.21.2 Key Products & Segments
144. 8.21.3 Financial Performance (2023–2025)
145. 8.21.4 Business Strategy
146. 8.21.5 SWOT Analysis
147. 8.21.6 Strategic Implications (2025–2031)
148. 8.22 QuidelOrtho Corporation
149. 8.22.1 Company Overview
150. 8.22.2 Key Products & Segments
151. 8.22.3 Financial Performance (2023–2025)
152. 8.22.4 Business Strategy
153. 8.22.5 SWOT Analysis
154. 8.22.6 Strategic Implications (2025–2031)
155. 8.23 Revvity, Inc.
156. 8.23.1 Company Overview
157. 8.23.2 Key Products & Segments
158. 8.23.3 Financial Performance (2023–2025)
159. 8.23.4 Business Strategy
160. 8.23.5 SWOT Analysis
161. 8.23.6 Strategic Implications (2025–2031)
9. Competitive Landscape
1. 9.1 Competitive Landscape Overview
2. 9.1.1 Market Share Concentration: Top 5 Players (Estimated, 2025)
3. 9.1.2 Concentration Metric
4. 9.1.3 Competitive Intensity and Structural Dynamics
5. 9.2 Competitive Intensity Assessment
6. 9.2.1 Tier Structure and Revenue Ranges
7. 9.2.2 Capacity vs. Demand Dynamics
8. 9.2.3 Pricing Environment
9. 9.2.4 Barriers to Entry and Exit
10. 9.3 Key Player Strategies & Positioning
11. 9.3.1 Strategic Group Narrative
12. 9.3.2 Differentiation Strategies Across Major Players
13. 9.3.3 Geographic Strongholds
14. 9.3.4 M&A and Partnership Activity, 2022–Present
15. 9.3.5 R&D and Technology Investment Trends
16. 9.4 Competitive Dynamics & Strategic Outlook
17. 9.4.1 Emerging Competitive Threats
18. 9.4.2 Consolidation vs. Fragmentation Outlook
19. 9.4.3 Competitive Response Matrix
20. 9.4.4 Strategic Recommendations, 2025–2031
10. Porter's Five Forces Analysis
1. 10.1 Threat of New Entrants
2. 10.2 Bargaining Power of Buyers
3. 10.3 Bargaining Power of Suppliers
4. 10.4 Threat of Substitutes
5. 10.5 Competitive Rivalry
11. PESTLE Analysis
1. 11.1 Political Factors
2. 11.1.1 Government Healthcare Investment and Diagnostic Infrastructure…
3. 11.1.2 Geopolitical Dynamics and Supply Chain Sovereignty
4. 11.1.3 Public Health Emergency Preparedness
5. 11.2 Economic Factors
6. 11.2.1 Macroeconomic Environment and Healthcare Spending Sensitivity
7. 11.2.2 Currency and Reimbursement Dynamics
8. 11.2.3 Emerging Market Economic Growth as a Structural Demand Driver
9. 11.2.4 M&A and Capital Market Environment
10. 11.3 Social & Demographic Factors
11. 11.3.1 Aging Global Population and Chronic Disease Prevalence
12. 11.3.2 Rising Consumer Health Awareness and Preventive Diagnostics
13. 11.3.3 Healthcare Accessibility and Equity
14. 11.4 Technological Factors
15. 11.4.1 Molecular Diagnostics and Next-Generation Sequencing
16. 11.4.2 Artificial Intelligence and Digital Pathology
17. 11.4.3 Point-of-Care Technology Maturation
18. 11.4.4 Companion Diagnostics and Precision Medicine
19. 11.5 Legal & Regulatory Factors
20. 11.5.1 Evolving Regulatory Frameworks
21. 11.5.2 Intellectual Property and Patent Dynamics
22. 11.5.3 Reimbursement Policy and Health Technology Assessment
23. 11.6 Environmental Factors
24. 11.6.1 Sustainability and Carbon Footprint in IVD Manufacturing
25. 11.6.2 Cold Chain and Supply Chain Resilience
26. 11.6.3 Climate Change and Infectious Disease Epidemiology
27. 11.7 PESTLE Summary Assessment
12. SWOT Analysis
1. 12.1 Introduction
2. 12.2 Market-Level Strengths
3. 12.2.1 Structural Demand Anchored by Disease Burden and Demographics
4. 12.2.2 Demonstrated, Primary-Source-Confirmed Revenue Growth at Scale
5. 12.2.3 Breadth and Segmentation Depth Supporting Revenue Diversification
6. 12.2.4 Innovation Investment Infrastructure and Technology Leadership
7. 12.2.5 Strong Incumbency Advantages and Installed-Base Lock-In
8. 12.3 Market-Level Weaknesses
9. 12.3.1 Material Intra-Market Growth Divergence Undermines Uniform For…
10. 12.3.2 Unusually Wide Third-Party Market-Size Estimate Dispersion
11. 12.3.3 Regulatory Complexity and Clinical Validation Burden
12. 12.3.4 Reimbursement and Pricing Pressure on Mature Testing Categories
13. 12.3.5 Product-Line Rationalisation Signals in Established Franchises
14. 12.4 Strategic Opportunities
15. 12.4.1 Genomic Sequencing and AI/ML Diagnostics Expansion
16. 12.4.2 Asia Pacific Healthcare Infrastructure Expansion
17. 12.4.3 Point-of-Care Testing Decentralisation
18. 12.4.4 Oncology and Liquid Biopsy Momentum
19. 12.4.5 M&A and Portfolio Consolidation Activity
20. 12.5 External Threats
21. 12.5.1 Geopolitical and Supply-Chain Disruption Risk
22. 12.5.2 Regulatory Tightening and Jurisdictional Divergence
23. 12.5.3 Reimbursement Environment Deterioration
24. 12.5.4 Technology Substitution and Platform Disruption
25. 12.5.5 Structural Market-Size Uncertainty Affecting Capital Allocatio…
26. 12.5.6 Competitive Intensity from Diversified Conglomerates
27. 12.6 Summary Strategic Implications
13. Future Trends & Outlook
1. 13.1 Overview
2. 13.2 AI-Assisted Diagnostic Interpretation
3. 13.2.1 Structural Drivers and Technology Maturation
4. 13.2.2 Competitive Landscape Implications
5. 13.2.3 Regulatory and Adoption Trajectory
6. 13.3 Genome-Sequencing-Based Infectious Disease Diagnostics
7. 13.3.1 Epidemiological Context and Market Rationale
8. 13.3.2 Market Size and Growth Positioning
9. 13.3.3 Competitive and Operational Considerations
10. 13.4 Point-of-Care Testing Expansion
11. 13.4.1 Structural Growth Dynamics
12. 13.4.2 Application Segments and Geographic Differentiation
13. 13.4.3 Regulatory and Connectivity Trends
14. 13.5 Long-Term Market Outlook (2032–2035)
15. 13.5.1 Post-Horizon Structural Considerations
16. 13.5.2 Macro-Structural Market Growth Assumptions
17. 13.6 Investment & M&A Activity Outlook
18. 13.6.1 Capital Allocation Trends
19. 13.6.2 M&A Target Landscape
20. 13.6.3 Venture and Growth Capital Dynamics

List of Exhibits

2.1 Exhibit 2.1: Forecast of Global (in USD Bn)
2.2 Exhibit 2.2: Forecast of Global Market YoY Growth Rate & CAGR Summary (in %)
2.3 Exhibit 2.3: Forecast of North America (in USD Bn)
2.4 Exhibit 2.4: Forecast of Europe (in USD Bn)
2.5 Exhibit 2.5: Forecast of Asia Pacific (in USD Bn)
2.6 Exhibit 2.6: Forecast of Latin America (in USD Bn)
2.7 Exhibit 2.7: Forecast of Middle East & Africa (in USD Bn)
3.8 Exhibit 3.8: Forecast of Immunoassays (in USD Bn)
3.9 Exhibit 3.9: Forecast of Molecular Assays (in USD Bn)
3.10 Exhibit 3.10: Forecast of The Core Lab (Clinical Chemistry) (in USD Bn)
3.11 Exhibit 3.11: Forecast of Point-of-Care (POC) Tests (in USD Bn)
3.12 Exhibit 3.12: Forecast of Microbiology and Virology (in USD Bn)
3.13 Exhibit 3.13: Forecast of Hematology (in USD Bn)
3.14 Exhibit 3.14: Forecast of Coagulation (in USD Bn)
3.15 Exhibit 3.15: Forecast of Histology and Cytology (in USD Bn)
3.16 Exhibit 3.16: Forecast of Blood Banking Services (in USD Bn)
4.17 Exhibit 4.17: Forecast of Infectious Diseases (in USD Bn)
4.18 Exhibit 4.18: Forecast of Oncology (in USD Bn)
4.19 Exhibit 4.19: Forecast of Cardiology (in USD Bn)
4.20 Exhibit 4.20: Forecast of Diabetes (in USD Bn)
4.21 Exhibit 4.21: Forecast of Other Applications (in USD Bn)
6.22 Exhibit 6.22: Forecast of North America (in USD Bn)
6.23 Exhibit 6.23: Forecast of United States (in USD Bn)
6.24 Exhibit 6.24: Forecast of Canada (in USD Bn)
6.25 Exhibit 6.25: Forecast of Rest of North America (in USD Bn)
6.26 Exhibit 6.26: Forecast of Europe (in USD Bn)
6.27 Exhibit 6.27: Forecast of Germany (in USD Bn)
6.28 Exhibit 6.28: Forecast of France (in USD Bn)
6.29 Exhibit 6.29: Forecast of United Kingdom (in USD Bn)
6.30 Exhibit 6.30: Forecast of Switzerland (in USD Bn)
6.31 Exhibit 6.31: Forecast of Netherlands (in USD Bn)
6.32 Exhibit 6.32: Forecast of Spain (in USD Bn)
6.33 Exhibit 6.33: Forecast of Rest of Europe (in USD Bn)
6.34 Exhibit 6.34: Forecast of Asia Pacific (in USD Bn)
6.35 Exhibit 6.35: Forecast of China (in USD Bn)
6.36 Exhibit 6.36: Forecast of Japan (in USD Bn)
6.37 Exhibit 6.37: Forecast of India (in USD Bn)
6.38 Exhibit 6.38: Forecast of South Korea (in USD Bn)
6.39 Exhibit 6.39: Forecast of Rest of Asia Pacific (in USD Bn)
6.40 Exhibit 6.40: Forecast of Latin America (in USD Bn)
6.41 Exhibit 6.41: Forecast of Brazil (in USD Bn)
6.42 Exhibit 6.42: Forecast of Argentina (in USD Bn)
6.43 Exhibit 6.43: Forecast of Rest of Latin America (in USD Bn)
6.44 Exhibit 6.44: Forecast of Middle East & Africa (in USD Bn)
6.45 Exhibit 6.45: Forecast of Saudi Arabia (in USD Bn)
6.46 Exhibit 6.46: Forecast of South Africa (in USD Bn)
6.47 Exhibit 6.47: Forecast of Rest of Middle East & Africa (in USD Bn)

bioMérieux S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd (Roche Diagnostics), Siemens Healthineers AG, Danaher Corporation, Thermo Fisher Scientific Inc., Becton Dickinson and Company (BD), Bio-Rad Laboratories Inc., QIAGEN N.V., Hologic Inc., Natera Inc., Seegene Inc., Werfen, Wiener Laboratorios S.A.I.C., Wama Diagnostica, Sysmex Corporation, Agilent Technologies Inc., Bruker Corporation, DexCom Inc., Exact Sciences Corporation, Illumina Inc., QuidelOrtho Corporation, Revvity Inc.

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Enterprise license fee.

Enterprise License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.